共 50 条
Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation
被引:12
|作者:
Webster-Clark, Michael
[1
]
Lund, Jennifer L.
[1
]
Sturmer, Til
[1
]
Poole, Charles
[1
]
Simpson, Ross J.
[2
]
Edwards, Jessie K.
[1
]
机构:
[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金:
美国国家卫生研究院;
关键词:
Anticoagulation;
Generalizability;
Medicare;
Older adults;
Transportability;
CLINICAL-TRIALS;
ORAL ANTICOAGULANTS;
STROKE PREVENTION;
ADVERSE EVENTS;
WARFARIN;
DABIGATRAN;
RIVAROXABAN;
APIXABAN;
OUTCOMES;
THERAPY;
D O I:
10.1097/EDE.0000000000001230
中图分类号:
R1 [预防医学、卫生学];
学科分类号:
1004 ;
120402 ;
摘要:
Background: Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. Methods: We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. Results: Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract:.
引用
收藏
页码:605 / 613
页数:9
相关论文